Please assess the completion status of the following clinical trial:

Trial Title: Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Women older than 18 years old.~* HER2 positive breast cancer with histological diagnoses.~* Non-operable locally advanced or metastatic disease, previously treated with trastuzumab and taxanes.~* Measurable or non-measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST).~* Disease progression during or after treatment with trastuzumab and taxanes.~* Maximum of 1 previous chemotherapy line for advanced or metastatic disease.~* Previous radiotherapy is allowed if radiated area is not the only documented lesion.~* At least 4 weeks since the last administration of antineoplastic treatment and all toxicities resolved.~* Performance status Eastern Cooperative Oncology Group (ECOG) \>=2.~* Life expectancy of at least 12 weeks.~* Left Ventricular Ejection Fraction (LVEF) evaluation (\>=50%) in previous 4 weeks.~* Hematology:~  * neutrophils \>=1.5 x 10e9/l;~ * platelets \>= 100 x 10e9/l;~ * hemoglobin \>= 10 mg/dl~* Hepatic function:~  * total bilirubin \<= 1.5 x under normal limit (UNL);~ * Aspartate aminotransferase (SGOT) and Alanine aminotransferase (SGPT) and alkaline phosphatase \<= 2.5 x UNL, or \<=5 x UNL if hepatic lesions present~* Renal function:~  * creatinine \<= 175 µmol/l (2 mg/dl);~ * creatinine clearance \>= 60 ml/min.~* Patients able to comply with treatment and follow-up.~* Negative pregnancy test in the previous 14 days. Adequate contraceptive method during treatment and up to 3 months after finalised.~* Brain metastatic lesions are allowed provided all other criteria are met.~* Male who met inclusion criteria are eligible.~Exclusion Criteria:~* History of hypersensitivity to vinorelbine, trastuzumab, rat proteins or trastuzumab components.~* History of dyspnea at rest, or chronic oxygen therapy required.~* Active infection.~* Second malignancy, except for cervical in situ carcinoma, basal skin carcinoma, adequately treated. Previous malignancies with a 5 year disease free survival are allowed.~* Pregnant or lactating women.~* Any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year, uncontrolled hypertension or high risk arrhythmias.~* History of neurological or psychiatric disorders, which could preclude the patients to free informed consent.~* Active uncontrolled infection.~* Active peptic ulcer, unstable diabetes mellitus.~* Concomitant treatment with other investigational products. Participation in other clinical trials with a non-marketed drug in the 30 previous days before randomization.~* Concomitant treatment with other therapy for cancer.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: VX (Type: ACTIVE_COMPARATOR): Vinorelbine and capecitabine (VX): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days).
- Arm B: VXH (Type: EXPERIMENTAL): Vinorelbine, capecitabine and trastuzumab (VXH): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days) and trastuzumab 4 mg/kg iv (loading dose first week), followed by 2 mg/kg weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).